CareLit Fachartikel

Treatment of chronic hepatitis C by Pegylated Interferon Alfa-2b (Peg2b) and Ribavirin (RBV): Age-and gender dependent frequency of hematological alterations in a German real-life…

G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Mölller, N Dikopoulos, J Brack, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2013 · Heft 08

Dokument
1142772
CareLit-ID
Jahr
2013
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Mölller, N Dikopoulos, J Brack, D Hartmann, B Dreher, M Bilzer
Ausgabe
Heft 08 / 2013
Seiten
–
Erschienen: 2013-08-16 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0033-1352958

Zusammenfassung

Aims: Peg2b in combination with RBV has been extensively explored for its efficacy in the treatment of chronic hepatitis C. Its use is accompanied by a variety of hematological side effects which may hamper reaching and maintaining the dose needed for maximal therapeutic effect. Data regarding the frequency of hematological side effects caused by Peg2b/RBV in real-life are still scarce and were therefore evaluated in the present analysis. Methods: Data from patients (pts) treated for G1 (N = 1873) and G2/3 infection (N = 1323) with Peg2b 1.5 µg/kg/week + weight-based RBV (800 – 1200 mg/day) for up to 48 weeks in…

Schlagworte

Hepatitis Germany Zeitschrift für Gastroenterologie